← Leaderboards
Charles Nichols
University Of Pennsylvania
$248,292
Attributed
$248,292
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$248,292 · 1
By mechanism
M01$248,292 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Pennsylvania
Same institution · by research overlap
- Rob R Macgregor$4,980,820
- Ian Frank$25,757,892
- Harvey Michael Friedman$28,257,678
- Peter J. Snyder$40,848,094
- Jane B Alavi$1,520,103
Others in their field
Top investigators on “Aids Therapy”
- Lawrence Corey · Fred Hutchinson Cancer Center$356,191,804
- Constance Ann Benson · University Of California, San Diego$277,003,036
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$262,875,323
- Barbara Driver · Westat, Inc.$205,980,213
- Sharon A Nachman · Johns Hopkins University$193,704,208
- Carol Nesel · Westat$188,148,170
Research focus
Aids TherapyCidofovirClinical ResearchCombination ChemotherapyCytomegalovirus RetinitisDrug Administration RoutesEye Disorder ChemotherapyGanciclovirHuman SubjectHuman Therapy Evaluation
Grant awards (6)
ACTG 350: GANICLOVIR/CIDOFOVIR CMV RETINITIS PHASE IV$124,146
M01 · FY2002 · RR
ACTG 350: GANICLOVIR/CIDOFOVIR CMV RETINITIS PHASE IV$124,146
M01 · FY2001 · RR
ACTG 350: GANICLOVIR/CIDOFOVIR CMV RETINITIS PHASE IV$0
M01 · FY2001 · RR
ACTG 350: GANICLOVIR/CIDOFOVIR CMV RETINITIS PHASE IV$0
M01 · FY2000 · RR
ACTG 350: GANICLOVIR/CIDOFOVIR CMV RETINITIS PHASE IV$0
M01 · FY2000 · RR
ACTG 350: GANICLOVIR/CIDOFOVIR CMV RETINITIS PHASE IV$0
M01 · FY2000 · RR